An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for mechanism questions, Phase 2 dose-ranging interpretation, and the specific analytical problems a 39-residue tri-agonist creates for purity testing.
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. This is presented as though it settles something, and I am not convinced it…
I am trying to understand the logic of putting glucagon receptor agonism into a weight-loss molecule, because on the face of it it sounds like a mistake. Glucagon…
I have the report as a PDF with the chromatogram on page two, so I can quote specifics. I can do the algebra. I am not confident about the conversion factors. If…
The label maximum gets treated as a destination — the "full dose", as though anything below it is partial. But a label maximum is the highest dose a sponsor took…
The obesity pipeline is currently full of phase 2 results being quoted as though they were established magnitudes. Retatrutide at -24.2% over 48 weeks is the…
The case in front of me: STEP 1 · liraglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
I am asking mechanistically rather than practically — I want the model, not the protocol. The comparison I want does not seem to exist anywhere in a form I can…
Setup, so nobody has to ask: SURMOUNT-4 · mazdutide. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all…
The receptor pharmacology I can follow; the in vivo translation is where I lose the thread. I would like the axes of comparison first and the recommendation second. I…
This matters because it predicts what a related molecule should do. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume…
I would like to know how much of this is established and how much is a reasonable story. I have used one of these for a while and I am considering switching, which…
The particulars: tirzepatide · ESSENCE. I understand the observation; what I do not understand is the mechanism behind it. I have read the two review articles that…
The clinician who ordered the panel was not concerned; I would still like to understand it. This is one of those things that everyone repeats and nobody derives. This…
What I am working with: 20 mg · mazdutide. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I would rather…
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse results